Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720689 | 0.83 | HRH3 (0.55) | HRH3L3MBTL1 | |
| SCHEMBL14723527 | 0.77 | HRH3 (0.52) | HRH3MAPK1L3MBTL1OGA | |
| SCHEMBL14720705 | 0.76 | ALDH1A1 (0.44) | HRH3NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL14720478 | 0.76 | GRM5 (0.44) | MAPK1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL14720473 | 0.76 | SRD5A2 (0.48) | HRH3NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL14721331 | 0.75 | HRH3 (0.45) | HRH3L3MBTL1 | |
| SCHEMBL14720367 | 0.75 | HRH3 (0.42) | HRH3KMT2APOLB | |
| SCHEMBL5450221 | 0.74 | HRH3 (0.55) | HRH3 | |
| SCHEMBL9204223 | 0.74 | HRH3 (0.73) | HRH3NPC1RAB9AKMT2AOGA | |
| SCHEMBL14721036 | 0.73 | HRH3 (0.35) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013027001-A1 | COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |